- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00968331
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
After this induction phase, the CR, PR and SD will continue Lenalidomide with the same schedule for other 8 months.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Bologna, Italien, 40138
- Institute Of Hematology "Seràgnoli"
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Understand and voluntarily sign an informed consent form.
- Be = 65 years of age at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements.
- Patients with histological confirmation of DLBCL.
- Stage of disease at study entry may include stage II-III-IV according to Ann Arbor Classification
- Patients must have failed at least one prior treatments
- ECOG performance status of equal or less than 2 at study entry
- nLaboratory test results within these ranges:
- Absolute neutrophil count equal or major than 1.0 x 109/L
- Platelet count equal or major than 50 x 109/L
- Serum creatinine equal or less than 2.0 mg/dL
- Total bilirubin equal or less than 1.5 mg/dL
- AST (SGOT) and ALT (SGPT) equal or less than 2 x ULN or equal or less 5 x ULN if hepatic metastases are present
- Hemoglobin equal or major than 8 g/dl
Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study:
- for at least 28days before starting study drug
- while participating in the study
- for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom,diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.
- Disease free of prior malignancies for equal or major 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast
- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. (patients intolerant to ASA may use warfarin or low molecular weight heparin).
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Use of any other experimental drug or therapy within 28 days of baseline.
- Known hypersensitivity to thalidomide.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Any prior use of lenalidomide.
- Concurrent use of other anti-cancer agents or treatments.
- Known positive for HIV or infectious hepatitis, type A, B or C.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: REVLIMID plus RITUXIMAB
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles. |
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To assess the antitumour activity of Lenalidomide plus Rituximab (REVLIRIT) as salvage treatment in elderly patients with relapsed or refractory DLBCL, in terms of Overall Response Rate (CR and PR)
Tidsramme: 12 months
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
To assess the overall feasibility of the REVLIRIT regimen in terms of response To assess the duration of response, TTP and PFS, safety and tolerability of the REVLIRIT regimen in terms of AE and SAE frequency and severity
Tidsramme: 12 months
|
12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom
- Lymfom, B-celle
- Lymfom, stor B-celle, diffus
- Lægemidlers fysiologiske virkninger
- Antirheumatiske midler
- Antineoplastiske midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Lenalidomid
- Rituximab
Andre undersøgelses-id-numre
- REVLIRIT01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diffust storcellet B-celle lymfom
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
National Cancer Institute (NCI)Trukket tilbageDiffust, stort B-cellet lymfom | Lymfom, diffust storcellet | Lymfom, diffus storcellet B-celle | Storcellet lymfom, diffust
-
Innovent Biologics (Suzhou) Co. Ltd.Afsluttet
-
Grupo Español de Linfomas y Transplante Autólogo...Janssen-Cilag, S.A.AfsluttetDiffus, stor B-celle, lymfomSpanien
-
Xinjiang Medical UniversityUkendtDiffus, stor B-celle, lymfomKina
-
Hoffmann-La RocheAfsluttetDiffus, stor B-celle, lymfomKina
-
BayerAfsluttetDiffus, stor B-celle, lymfomBelgien, Frankrig, Canada, Korea, Republikken, Australien, Tyskland, Det Forenede Kongerige, Italien, Danmark, Singapore
-
University of Southern CaliforniaAfsluttetDiffus, stor B-celle, lymfomForenede Stater
-
Neumedicines Inc.UkendtLymfom, stor B-celle, diffus (DLBCL)
-
Nantes University HospitalAfsluttetLymfom, storcellet, diffusFrankrig
Kliniske forsøg med Lenalidomide plus Rituximab
-
Swiss Group for Clinical Cancer ResearchAfsluttetLymfomSchweiz, Norge, Sverige
-
Institut Paoli-CalmettesAfsluttetNon-Hodgkin lymfomFrankrig
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Trukket tilbage
-
Fondazione Italiana Linfomi - ETSAktiv, ikke rekrutterende
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Afsluttet
-
Arbeitsgemeinschaft medikamentoese TumortherapieAfsluttetLymfom i det mucosa-associerede lymfoide væv (MALT)Østrig
-
Guangdong Provincial People's HospitalGuangzhou First People's Hospital; Foshan First People's Hospital; Huizhou... og andre samarbejdspartnereRekrutteringDiffust storcellet B-celle lymfom | Alder over 80 årKina
-
Kim, Seok JinCelltrion; Samyang Biopharmaceuticals CorporationRekrutteringPrimært CNS lymfomKorea, Republikken
-
Weill Medical College of Cornell UniversityCelgeneAfsluttet
-
Henan Cancer HospitalRekruttering